Kornimate/medical-research-clean huggingface dataset:
what is the workload burden associated with using the triage hf+ care pathway?

Conditions: Heart Failure

Summary: this observational, prospective real-world evaluation will estimate and characterize the heart-failure related clinical workload burden associated with implementing a new care pathway (triage-hf plus) for remote monitoring and management in a cohort of device patients at 3 hospital sites in north west england as compared to the heart-failure related clinical workload burden prior to using this new care pathway. triage-hf plus incorporates the triage-hf algorithm which is a device-based algorithm that uses the input from the integrated device diagnostics to detect changes in physiological parameters which may indicate an individual's increased risk of heart failure event in the 30 days after a high triage-hf score.


Eligibility criteria:
inclusion criteria: * patient implanted with a medtronic icd, crt-d, or crt-p device that is triage-hf compatible and capable of automated transmission. note: remote monitoring data will not be available for 60 days post a new or replacement implant but patients can be enrolled in the evaluation any time after implant. * patient (or patient's legally authorized representative) is willing and able to provide written informed consent. * patients with carealerts already turned on will be included in the prospective part of the evaluation but their data may be excluded from the pre-triage-hf plus (current state) data analysis. * patients willing and able to have carelink monitor active at all times. exclusion criteria: * patient is enrolled in another conflicting evaluation/study that could confound the results of this evaluation by increasing clinic workload burden for that patient and/or impact clinical interventions and patient outcomes * all patients with non-triage-hf compatible devices * all patients with devices that require manual transmission (non-automated) * patient is unwilling or unable to comply with the protocol, including follow-up visits and carelink transmissions.
comprehensive hiv and harm prevention via telehealth

Conditions: HIV Infections

Summary: the purpose of this study is to test 2 different ways to offer medications to prevent human immunodeficiency virus (hiv), cure hepatitis c virus (hcv) (if applicable) and treat substance use disorder (if desired) in people who inject drugs.


Eligibility criteria:
inclusion criteria: * age 18 or older * able to speak english or spanish * willing and able to sign informed consent, provide locator information and medical records release * non-reactive result on rapid hiv test * use of ssp to exchange syringes 2 times in the past 3 months * planning to stay in the area for 12 months exclusion criteria: * reactive hiv test * currently on medications for opioid use disorder (moud) by urine drug screen * currently on prep by self-report * principal or site investigator discretion * currently in prison or jail * current enrollment in clinical trials network 121 * receipt of tele-harm reduction in previous 3 months * signs or symptoms of acute hiv infection
glycemic gap versus admission plasma glucose level as predictors of icu out comes in type 2 diabetic patients with acute heart failure

Conditions: Assess the Relation Between Glycemic Gab and Adverse Clinical Outcomes in Diabetic Patients Who Hospitalized With Heart Failure

Summary: assess the relation between glycemic gab and adverse clinical outcomes in diabetic patients who hospitalized with heart failure

hyperglycemia is a common problem in patients wi9non-diabetic patients but not in patients with diabetes . the relationship between admission hyperglycemia and mortality in diabetic patients with ahf or critical illness remains controversial . those discrepancies could be partly attributed to long-term glycemic control in diabetic patients. critical illness can induce stress-induced hyperglycemia (sih), which results from the excess release of counter-regulatory hormones and anti-inflammatory cytokines, leading to augmented gluconeogenesis and insulin resistance. in diabetic patients with acute illness, the phenomenon of admission hyperglycemia could be connected with acute physiological stress, poorer glycemic controls, or a combination of both . it is necessary to think about background glycemic control when exploring the relationships between admissions hyperglycemia and clinical outcomes. recent studies have shown that hemoglobin a1c (hba1c)-based adjusted glycemic variables, including glycemic gap and stress hyperglycemia ratio, were linked to severity of disease and unfavorable prognosis in diabetic patients with some infectious diseases, cardiovascular diseases and clinical illness

Eligibility criteria:
inclusion criteria: * all diabetic patients admitted to icu of internal medicine department from october 2020 to november 2021 by heart failure exclusion criteria: * age ≤18 years. 1. hypoglycemia (plasma glucose \<70 mg/dl) at initial presentation. 2. an admission diagnosis of diabetic ketoacidosis or hyperosmolar hyperglycemic state. 3. patients with hemoglobin variants (e.g., sickle cell anemia, thalassemia) or with hematologic conditions (e.g., hemolytic anemia) that could interfere with the accuracy of the hba1c assay.
biomechanics of optic neuropathy

Conditions: Optic Neuropathy

Summary: the participant is being asked to be a subject in this research study because the participant may have a disorder that can cause optic nerve damage and impairment of his/her visual function which is called optic neuropathies (on). optic neuropathy refers to damage to the optic nerve (a "cable" connecting the eyes and the brain to transmit the visual signals) due to any cause.in this study, the investigator is using magnetic resonance imaging (mri) and ophthalmic measures such as optic coherent tomography(oct), which are non-invasive imaging tests to measure the changes in eye globe shape ,the flow of blood and brain fluid. it is hoped that this study will provide new knowledge that may allow the investigator to better understand the cause of symptoms associated with optic neuropathy and ways to better monitor what is happening.


Eligibility criteria:
inclusion criteria : * 18 years old and on * patients with optic neuropathy(10) and age controlled healthy subjects(10) exclusion criteria : * for patients: subjects with history of neurological or ocular disease other than optic neuropathy and refractory error. * for healthy control group: history of systemic disease except hypertension. * pregnant women and prisoners will be excluded.

Keywords: glaucoma leber optic neuropathy anterior ischemic optic neuropathy
osteopontin gene polymorphism in stroke patients in egypt

Conditions: Ischemic Stroke

Summary: this study aims to investigate the correlation of serum osteopontin level as a predictior and a prognostic factor in upper egyptian patients and correlation between osteopontin gene polymorphisms and serum level of osteopontin in ischaemic stroke patients

the global burden of disease estimated that one person in four aged 25 years will have a stroke in the rest of her/his life. among them, ischemic stroke (is) represents 80%. stroke is accompanied by a neuroinflammatory response involving immune system. these long-term processes following is are still far from being understood. so, despite the significant improvement in the diagnosis and treatment of is, the disability and mortality rate of is are still rising. an assessment of the prognostic risk of is should be carried out as early as possible and corresponding interventions should be adopted clinically, in order to have a significant impact on the prognosis of patients with is. predicting the outcome in individual patients solely based on clinical and radiological parameters is challenging for clinicians. measuring blood biomarkers associated with inflammation, endothelial function, matrix remodeling, and immune functions, may improve prediction performance . osteopontin (opn) is a matricellular protein participating in many physiological and pathologic processes including wound healing, bone turnover, tumor genesis, inflammation, and immune responses . it is well accepted that opn is an important mediator in stroke pathophysiology. opn expression is upregulated in microglia surrounding the infarcted area and in microglia and infiltrating macrophages in the infarct area. opn and microglia seems to exhibit an intimate relationship in stroke with rather beneficial functions for the clinical outcome. however, the role of opn in stroke-related diseases as atherosclerosis and diabetes should be further disentangled as in this early phase of disease opn may ultimately culminate in cerebrovascular dysfunction. opn may exert opposing effects and should be therefore addressed differently.

Eligibility criteria:
inclusion criteria: * for acute ischemic stroke cases: ( acute ischemic stroke will be defined as an episode of focal neurological deficits lasting for more than 24 hour with relevant lesion in brain computerized tomography (ct) or magnetic resonance (mr) image\>) 1- both sex 2- age between 18 to 70 years old. 3-symptoms suggestive of acute ischemic stroke: presenting within 24 hours of onset of these symptoms * for old ischemic stroke: 1. both sex 2. age between 18 to 70 years old. 3. duration of3to 6 month of development of ischemic symptoms * for control cases: 1. both sex 2. healthy people 3. age: above 18 years old exclusion criteria: patients with a previous history of stroke; patients with hemorrhagic stroke. patients with coronary heart disease, heart failure, chronic inflammation, intracranial infection/brain tumor and malignant tumor. patients with liver, kidney and other important organ dysfunction. patients with severe abnormal coagulation function
a study of shr2554 with chemotherapy in treatment-naïve patients with peripheral t-cell lymphoma

Conditions: Peripheral T-cell Lymphoma

Summary: the study is being conducted to evaluate the safety and efficacy of shr2554 with chop/choep in treatment- naïve peripheral t-cell lymphoma.


Eligibility criteria:
inclusion criteria: 1. males or females aged 18-70 years (inclusive); 2. histologically confirmed peripheral t-cell lymphoma; 3. eastern cooperative oncology group performance status (ecog ps) score of 0 or 1; 4. life expectancy ≥ 12 weeks; 5. have measurable lesions ; 6. the subject is willing and able to comply with the visit schedule, dosing schedule, laboratory tests, and other clinical study procedures. exclusion criteria: 1. underwent major surgery or experienced severe trauma within 4 weeks prior to the first dose of the investigational drug; 2. known active hbv or hcv infection; 3. history of clinically significant cardiovascular disease; 4. history of other malignancies within 5 years; 5. pregnant or lactating women; 6. based on the investigator's judgment, there are objective conditions that may prevent the subject from completing the study as planned or the subject has other factors, concomitant diseases, concomitant treatments, or abnormal laboratory findings that may lead to early study termination.
taking a look at patient experiences in rectal cancer clinical trials

Conditions: Rectal Cancer

Summary: the primary objective of this research study is to explore the barriers encountered by specific demographic groups of rectal cancer patients during the engagement in clinical trials, which historically lack diverse representation. by carefully analyzing data from various demographic perspectives, this study aims to uncover patterns that impact the experiences of future rectal cancer patients. active involvement in this crucial research is of utmost importance, as it can offer unique insights to enhance the participation and completion rates of rectal cancer patients in clinical study.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of rectal cancer * aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed * no prior treatment for rectal cancer exclusion criteria: * pregnant or lactating woman * inability to provide written informed consent * enrolled in another research study

Keywords: rectal cancer
study of khk2823 in patients with acute myeloid leukemia (aml) and myelodysplastic syndrome (mds)

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome

Summary: this is a first in human, non-randomized, open-label, dose escalation study to investigate the safety, pharmacokinetics, immunogenicity and pharmacodynamics of repeat doses of khk2823.

this is a phase 1, multi-center, open-label, dose-escalation study of khk2823 in adult patients with previously untreated aml who are not candidates for intensive remission induction therapy; relapsed/refractory aml for whom no other standard therapy is available or appropriate; or relapsed/refractory mds who have received prior therapy with a hypomethylating agent, such as decitabine and azacitidine or who are not candidates to receive a hypomethylating agent, this would include high risk or transfusion-dependent low risk patients. patients must have documented primary or secondary aml or mds according to world health organization (who) criteria. following the provision of signed informed consent, patients will be screened for entry into the study. the study consists of 2 parts. in part 1, 3 to 6 patients per cohort will be enrolled sequentially in up to 7 dose-escalation cohorts to establish the mtd. khk2823 will be administered once weekly. in part 2, up to an additional 18 patients may be enrolled to further evaluate the safety, pk, pd, potential anti-leukemic activity of khk2823.

Eligibility criteria:
inclusion criteria: * males and females ≥ 18 years old with previously untreated aml who are not candidates for intensive remission induction therapy; relapsed/refractory aml for whom no other standard therapy is available or appropriate; or relapsed/refractory mds who have received prior therapy with a hypomethylating agent or who are not candidates to receive a hypomethylating agent * histopathologically/cytologically documented primary or secondary aml, as defined by who criteria, or mds, confirmed by pathology review at treating institution * eastern cooperative oncology group (ecog) performance status score of 0-2 * life expectancy of at least 3 months exclusion criteria: * histological diagnosis of acute promyelocytic leukemia (fab type m3) * clinically significant central nervous system leukemia * treatment of the underlying hematologic condition with systemic therapy during the treatment period, including any chemotherapy, radiation or investigational therapy, within 2 weeks prior to khk2823 administration; or immunotherapy within 30 days prior to khk2823 administration; with the exception of hydroxyurea (hydrea®) for treatment of hyperleukocytosis, which must be discontinued at least 24 hours prior to the first dose of khk2823
aflo™ device trial

Conditions: Asthma; Asthma in Children

Summary: this randomised, prospective, controlled parallel study aims to evaluate the role and potential of the aflo™ digital platform for improving asthma control, inhalation technique and adherence in patients who use metred dose inhalers (mdi). the study will recruit 104 patients with uncontrolled asthma in the north-west of northern ireland. fifty two patients will remain on standard care over 24-weeks and 52 will combine standard care with the aflo™ platform. the data collected over a 24-week period will be used to determine 1. whether the aflo™platform improves inhalation technique and user adherence to prescribed medication and 2. lead to better asthma control and reduced symptoms as measured by the asthma control test (act). during the study clinicians will be able to remotely monitor and review user analytics via a clinical dashboard. act measurements will be recorded at start and end of study. the study aims to test the functionality and impact of automated inhaler technique with real-time feedback, adherence prompts and air quality data sharing for patients who use metered dose inhalers (mdi) using the newly developed aflo™ digital respiratory management platform.


Eligibility criteria:
inclusion criteria: * confirmed as suitable for inclusion by their general practitioner or asthma nurse. * access to wifi and a smart phone (android or apple phone with latest version -2) and knowledge of / carer support with using a smartphone. * for children (parent/ carer must register and provide smart phone access) * aged \> 5 years (with carer/ parental consent if \< 17 years old) * smart phone user/ willing to use (or parent/ carer) and have access to and knowledge of working a smart phone and wifi / 4g * currently prescribed an inhaled reliever +/- preventer medication via pressurised * metered dose inhaler (mdi) short acting beta2 agonist (saba), inhaled corticosteroid (ics) ics / long acting beta2 agonist (laba) mdi +/- spacer * adherence/ symptom control issues with medication (as identified by excess use of saba/ healthcare personnel visits/ calls/ emergency department visit/ hospital admission * those who understand written and spoken english exclusion criteria: * \< 5 years old * other major respiratory illness or significant concurrent disease that might prevent completion of the study

Keywords: asthma asthma control respiratory management platform medical device inhaler technique
studying biomarkers in cell samples from patients with acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is looking at biomarkers in cell samples from patients with acute myeloid leukemia.

objectives: * to determine the significance of regulation of microrna-34a and microrna-194 by c/ebpα during granulopoiesis in patients with acute myeloid leukemia with cebpa mutations. * to determine whether overexpression of micro rna-34a and microrna-194 in myeloid progenitors with c/ebpα mutations leads to granulocytic differentiation. * to examine how microrna-34a and microrna-194 downregulate e2f3 during granulopoiesis. * to determine the role of microrna-34a and microrna-194 in myeloid cell proliferation. outline: cryopreserved cell samples are collected for laboratory analysis, including mutation analysis, gene expression analysis, rna analysis, and fluorescence-activated cell sorting (facs) analysis.

Eligibility criteria:
disease characteristics: * diagnosis of acute myeloid leukemia with cebpa mutations patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: adult acute myeloid leukemia childhood acute myeloid leukemia/other myeloid malignancies
the study of surgery,chemotherapy and autologous t cells-based immunotherapy for advanced gastric cancer.

Conditions: Gastric Cancer.

Summary: evaluate the feasibility ,safety and efficacy of surgery，chemotherapy in combination with autologous t cells-based immunotherapy for advanced gastric cancer.

safety:ae/sae efficacy:immunologic function;fps

Eligibility criteria:
inclusion criteria: * aged between 18 to 80 years, males and females. * subjects who understand and sign the consent form for this study. * the pathologically confirmed advanced gastric cancer t3、t4 or t2 and metastasis in lymph nodes. * subjects are surgical candidates. * no distant metastasis (m0) and no distant lymph node metastasis. * expected survival time of at least 6 months. exclusion criteria: * subjects who do not sign the consent form for this study. * the subject has an allergic history of medicine or food. * the subject has uncontrolled or hard-to-control diseases of cardiovascular,liver,kidney or lung,endocrine system. * the subject tests positive for: hiv, hepatitis virus, syphilis or other infectious diseases. * the subject has an history of other malignant tumour. * the subject has history of alcoholism, drug abuse, or mental illness in the 12 years prior to this trial. * the subject has participated in any other clinical trial in the 3 months prior to this trial. * the subject is pregnant, lactating or planning to conceive within the next 24 months. * the subject has any other unsuitable or adverse condition to be determined by the investigator.
the safety and effectiveness of ganciclovir plus interferon beta in preventing the return of cytomegalovirus (cmv) of the eyes in patients with aids

Conditions: Cytomegalovirus Retinitis; HIV Infections

Summary: the use of ganciclovir (dhpg) in combination with interferon beta to prevent relapse of cytomegalovirus retinitis in patients with aids. while early clinical trials have shown that 30 mg/kg/week of dhpg is usually sufficient to delay or prevent relapse, neutropenia is a common dose-limiting problem in about 50 percent of patients. since in vitro data have suggested that there is synergism between dhpg and interferon beta against cytomegalovirus, a reduced dose of dhpg in combination with a low dose of interferon beta may prevent relapse without causing neutropenia. if remission can be maintained with low-dose dhpg and interferon beta, maintenance therapy with a moderate dose of interferon beta alone will be evaluated in a subsequent protocol.


Eligibility criteria:
inclusion criteria patients must fulfill the cdc criteria for the diagnosis of aids. in addition, patients must have a typical clinical picture of cytomegalovirus (cmv) retinitis, a positive cmv culture from any site, and no other possible explanation for the retinal findings (e.g., toxoplasmosis infection). patients with aids in whom cmv retinitis is suspected will be examined by an ophthalmologist and, if, retinal lesions are seen, shall have a complete set of retinal photographs taken. cmv cultures of throat, buffy coat, urine, and if possible, semen will be obtained. * cytomegalovirus and toxoplasmosis serologic (igg and igm) tests will also be performed. exclusion criteria co-existing condition: patients not meeting inclusion criteria are excluded. patients not meeting inclusion criteria are excluded.

Keywords: retinitis aids-related opportunistic infections ganciclovir drug therapy, combination cytomegalovirus infections acquired immunodeficiency syndrome interferon type i